Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model

BACKGROUND: In 2017, the FDA approved the adjuvanted recombinant zoster vaccine (RZV) for the prevention of herpes zoster (HZ) in immunocompetent adults aged 50 years and older. RZV joined zoster vaccine live (ZVL) as U.S.-marketed vaccines against HZ. The Advisory Committee on Immunization Practice...

Descripción completa

Detalles Bibliográficos
Autores principales: Patterson, Brandon J, Herring, William L, Van Oorschot, Desiree, Curran, Desmond, Carrico, Justin, Zhang, Yuanhui, Ackerson, Bradley K, Bruxvoort, Katia, Sy, Lina S, Tseng, Hung-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391059/
https://www.ncbi.nlm.nih.gov/pubmed/33043821
http://dx.doi.org/10.18553/jmcp.2020.20251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391059/
https://www.ncbi.nlm.nih.gov/pubmed/33043821
http://dx.doi.org/10.18553/jmcp.2020.20251

Ejemplares similares